Introduction {#sec1}
============

Chronic cor pulmonale (CCP), a common type of heart disease, has become a rising major public problem that threatens people's health and quality of life around the world \[[@B1]\]. Although the term "cor pulmonale" is popular in the medical literature, there is presently no consensual definition \[[@B1]\]. World Health Organization (WHO) defined CCP as "hypertrophy of the right ventricle resulting from diseases affecting the function and/or structure of the lungs, and may further leading to heart failure" \[[@B4]\]. Pulmonary hypertension resulting from disorders of the respiratory system and/or from chronic hypoxaemia is the main pathological mechanism of CCP \[[@B1],[@B5],[@B6]\]. Currently, the conventional treatment, including antibiotics, vasodilators, expectorants, antiasthmatic drugs, diuretics and antiarrhythic drugs etc. is the main clinical therapy for CCP \[[@B1]\]. However, it is universally acknowledged that long-time use of western medicine sometimes may cause drug resistance and toxic side effects, and therefore its clinical efficacy is still unsatisfactory \[[@B1],[@B2]\]. Many researchers in China and some other Asian countries indicated that the combination of Chinese and Western medicine for CCP might be the potential trend of clinical treatment development in future \[[@B7]\].

Ginkgo leaf extract and dipyridamole injection (GLED) is a compound Chinese herbal medicine, which mainly consists of ginkgo flavone glycosides (24--25%), terpene lactones \[ginkgolides (3.1%) and bilobalide (2.9%)\] and dipyridamole (10%) \[[@B13]\]. Ginkgo leaf extract has been proved to be an antioxidant and free radical scavenger, an inhibitor of the platelet-activating factor, a vasodilator, and a regulator of metabolism \[[@B14]\]. The therapeutic effect mechanism of GLED on CCP included its ability to scavenge free radicals, reduce inflammation and platelet aggregation while regulating vasodilation and glucose and lipid metabolism \[[@B16]\]. Furthermore, GBE affects vasomotor functions by modulating the synthesis of vasoactive substances including nitric oxide and endothelin \[[@B16]\]. GLED is a combination of Ginkgo leaf extract and dipyridamole (a kind of anti-thrombus and vasodilator drug) \[[@B18]\], and has the pharmacological characteristics of both. GLED has been considered as a promising supplementary treatment option for cardiovascular disease, peripheral vascular disease and pulmonary disease due to its unique biological characteristics \[[@B13]\]. Tan et al. \[[@B14]\] reported that GLED (10--40 ml/day per day via intravenous infusion) could relieve the incidence of angina pectoris and improve the hemorheology index of patients with coronary artery disease. Xue et al. \[[@B15]\] showed that the clinical application of GDI (10--40 ml/day per day via intravenous infusion) not only obviously enhanced the overall response rate of conventional treatments, but also effectively improved the blood viscosity and blood lipid level of ischemic stroke patients.

Currently, its application in CCP is garnering much attention \[[@B14],[@B19]\]. Several clinical trials reported that conventional treatments combined with GLED exhibits more prominent therapeutic effects for CCP than conventional treatments alone \[[@B24]\]. However, the scientific evidence has not been systematically reviewed. In the present study, we conducted a meta-analysis to investigate the clinical efficacy and safety of GLED for CCP, in order to provide the best available evidence for clinical practice and further research planning on CCP treatment.

Materials and methods {#sec2}
=====================

This systematic review and meta-analysis was performed following the PRISMA guidelines and Cochrane Handbook. Ethics approval was not necessary due to the nature of the study (i.e. meta-analysis).

Search strategy {#sec2-1}
---------------

Literatures were searched across nine electronic databases, including PubMed, Embase, Web of Science, Cochrane Library, Medline, Chinese Scientific Journal Database (VIP), Wanfang database, China National Knowledge Infrastructure (CNKI) and Chinese Biological Medicine Database (CBM), before December 2019, with key terms "ginkgo biloba" or "ginkgo leaf extract" or "ginkgo dipyidamolum" and "dipyridamole injection" or "Ginkgo leaf extract and dipyridamole injection" or "yinxingdamo injection" and "pulmonary heart disease" or "chronic cor pulmonale" or "cor pulmonale" or "fei yuan xing xin zang bing" or "fei xin bing" (Supplementary Table S1). Language is limited with English and Chinese.

Eligibility criteria {#sec2-2}
--------------------

Inclusion criteria: Randomized controlled trials (RCTs) concerning patients diagnosed with CCP were included;Articles involving more than 50 CCP patients;There were no other medicines in combination with the conventional treatments in the experimental group, except for GLED, compared with the conventional treatments as a control;One or more outcome measures, including the therapeutic effect, or hemorheology or blood gas indexes, or adverse events must be included in each study.

Exclusion criteria: Studies not focus on GLED were excluded;Inappropriate criteria in experimental or control group were excluded;Articles without sufficient available data were excluded;Non-RCTs, literature reviews, meta-analysis, meeting abstracts and case reports, repeated studies and experimental model researches were excluded.

Data extraction and quality assessment {#sec2-3}
--------------------------------------

Data were extracted by two reviewers (Guo, Y. J. and Xu, X.) independently according to the same inclusion and exclusion criteria; disagreements were adjudicated by the third investigator (Yue, H. M.). The extracted characteristics comprised the following items: (a) first authors' names, (b) years of publication, (c) NYHA heart function classification, (d) number of cases, (e) patient ages, (f) intervening measure, (g) dosage of GLED, (h) duration of treatment, (i) manufacturer of GLED and (j) study parameter types. The quality of included trials was evaluated according to Cochrane Handbook \[[@B52],[@B53]\].

Outcome definition {#sec2-4}
------------------

Treatment efficacy was evaluated in terms of markedly effective rate (MER) and the total effective rate (TER), blood gas and hemorrheology indexes. The hemorrheology indexes covered the following indicators: plasma viscosity (PV), whole blood high-shear viscosity (WBHSV), whole blood medium-shear viscosity (WBMSV), whole blood low-shear viscosity (WBLSV), hematocrit, erythrocyte aggregation index (EAI) and content of fibrinogen (FBG). The blood gas indicators \[partial pressure of oxygen (PaO~2~), partial pressure of carbon dioxide (PaCO~2~), saturation of hemoglobin with oxygen (SaO~2~) and pH value\] of CCP patients were also determined and compared between the GLED and non- GLED groups.

Statistical analysis {#sec2-5}
--------------------

Statistical analysis was performed using the Review Manager 5.3 (Nordic Cochran Centre, Copenhagen, Denmark) and Stata 13.0 (Stata Corp., College Station, TX, U.S.A.) statistical software. Dichotomous data were represented by the risk ratio (RR) with the respective 95% confidence interval (CI), whereas continuous variables were expressed as mean difference (MD) with 95% CI. *P* \< 0.05 indicates difference with statistical significance. Cochrane's *Q*-test and *I*^2^ statistics were used to assess heterogeneity between studies; *P* \< 0.1 or *I*^2^ \> 50% indicates statistical heterogeneity \[[@B54]\]. A fixed-effects model was used to pool the estimates when heterogeneity was absent. Otherwise, a random effects model was selected.

Publication bias was evaluated by Begg's and Egger's regression tests \[[@B55]\]. If publication bias existed, a trim-and-fill method should be applied to coordinate the estimates from unpublished studies, which were compared with the original pooled RR \[[@B56]\]. Sensitivity analysis was conducted to investigate the influence of different GLED dosages, duration of treatment, sample sizes of involved studies, and manufacturer of GLED on clinical efficacy.

Results {#sec3}
=======

Search results {#sec3-1}
--------------

A total of 1722 articles were identified with initial retrieve. A total of 1395 papers were excluded due to duplication. After title and abstract review, 246 articles were further excluded because they were not clinical trials (*n* = 171) or were unrelated studies (*n* = 59) or were reviews and meta-analysis (*n* = 7) or were meeting abstracts and case report (*n* = 9), leaving 81 studies as potentially relevant. After detailed assessment of full texts, articles were not RCTs (*n* = 16), publications with inappropriate criteria of experimental or control group (*n* = 29) and trials with insufficient data (*n* = 8) were excluded. Finally, 28 trials \[[@B24]\] involving 2457 CCP patients were included in this analysis ([Figure 1](#F1){ref-type="fig"}).

![Study selection process for the meta-analysis](bsr-40-bsr20200099-g1){#F1}

Patient characteristics {#sec3-2}
-----------------------

After selection, all included trials were performed in different hospital of China. In total, 1214 CCP patients were treated by conventional treatments in combination with GLED adjuvant therapy, while 1243 patients were treated by conventional treatments alone. Detailed information of the involved studies and CCP patients is shown in [Table 1](#T1){ref-type="table"}. All included trials except two \[[@B36],[@B43]\] clearly introduce the duration of treatment. Fourteen studies \[[@B24],[@B34],[@B35],[@B41],[@B45],[@B46],[@B50]\] specifically describe the manufacturer of GLED and the remaining 14 studies \[[@B32],[@B33],[@B36],[@B42],[@B47],[@B51]\] lacked clear description of production information (Supplementary Table S2).

###### Clinical information from the eligible trials in the meta-analysis

  Included studies     NYHA classification   Patients Con/Exp   Age (year)            Intervening measure (Exp/Con)   Dosage of GLED       Duration       
  -------------------- --------------------- ------------------ --------------------- ------------------------------- -------------------- -------------- --------------
  Fan, J., 2011        II-IV                 40/40              63 ± 5.6 (mean)       61 ± 7.8 (mean)                 CT+GLED (iv) VS CT   20 ml/day      14 days
  Gan, L., 2015        II-IV                 43/43              67.00 ± 1.48 (mean)   68.50 ± 1.20 (mean)             CT+GLED (iv) VS CT   20 ml/day      10---14 days
  Gao, L. S., 2006     NG                    48/48              NG                    NG                              CT+GLED (iv) VS CT   20 ml/day      7 days
  Gao, L. Y., 2009     NG                    40/40              58 ± 11 (mean)        59 ± 11 (mean)                  CT+GLED (iv) VS CT   20 ml/day      14 days
  He, F. Z., 2009      III-IV                35/36              46--78 (range)        45--80 (range)                  CT+GLED (iv) VS CT   20 ml/day      14 days
  He, H., 2019         NG                    31/31              68 ± 9 (mean)         68 ± 10 (mean)                  CT+GLED (iv) VS CT   20 ml/day      12 days
  He, K. X., 2012      III-IV                31/31              62.41 ± 3.52 (mean)   62.36 ± 3.61 (mean)             CT+GLED (iv) VS CT   20 ml/day      7--14 days
  Hu, Z. W., 2013      NG                    40/40              59.2 ± 5.6 (mean)     60.2 ± 5.2 (mean)               CT+GLED (iv) VS CT   20 ml/day      10 days
  Jia, X. H., 2009     II-IV                 33/33              41--82 (range)        42--78 (range)                  CT+GLED (iv) VS CT   40 ml/day      15 days
  Ji, N. P., 2010      II-IV                 48/58              58--89 (range)        60--91 (range)                  CT+GLED (iv) VS CT   20 ml/day      10 days
  Liang, Y. M., 2007   III-IV                48/48              NG                    NG                              CT+GLED (iv) VS CT   30 ml/day      14 days
  Liu, L. Q., 2012     NG                    64/64              64.5 ± 8.9 (mean)     63.8 ± 8.6 (mean)               CT+GLED (iv) VS CT   20 ml/day      10 days
  Liu, R. P., 2009     II-IV                 31/30              50--79 (range)        51--79 (range)                  CT+GLED (iv) VS CT   15-20 ml/day   NG
  Li, W. M., 2009      NG                    51/52              49--92 (range)        45--95 (range)                  CT+GLED (iv) VS CT   20 ml/day      14 days
  Li, X. D., 2016      III-IV                45/45              60.89 ± 3.87 (mean)   61.02 ± 3.76 (mean)             CT+GLED (iv) VS CT   20 ml/day      7--14 days
  Tao, L., 2015        II-IV                 54/54              NG                    NG                              CT+GLED (iv) VS CT   30 ml/day      14 days
  Wang, B. C., 2011    III-IV                28/28              63.1 ± 3.9 (mean)     62.2 ± 4.3 (mean)               CT+GLED (iv) VS CT   20 ml/day      15 days
  Wang, L. H., 2014    II-IV                 56/56              71.8 ± 6.5 (mean)     72.5 ± 6.9 (mean)               CT+GLED (iv) VS CT   20 ml/day      10 days
  Wang, Y., 2017       II-III                36/36              NG                    NG                              CT+GLED (iv) VS CT   20 ml/day      10 days
  Xie, J., 2012        NG                    50/50              67.0 ± 6.5 (mean)     68.0 ± 7.0 (mean)               CT+GLED (iv) VS CT   20 ml/day      NG
  Xu, C. H., 2008      NG                    40/46              55.4 ± 7.8 (mean)     58.6 ± 7.3 (mean)               CT+GLED (iv) VS CT   15 ml/day      7 days
  Yang, J. L., 2010    III-IV                30/30              NG                    NG                              CT+GLED (iv) VS CT   20 ml/day      7--10 days
  Yang, Y. P., 2011    III-IV                35/35              41.5--79 (range)      40--80 (range)                  CT+GLED (iv) VS CT   20 ml/day      14 days
  Yin, Y. W., 2008     II-IV                 29/36              38--83 (range)        40--81 (range)                  CT+GLED (iv) VS CT   40 ml/day      15 days
  Zhong, G. N., 2015   NG                    60/60              68.36 ± 5.24 (mean)   68.41 ± 5.33 (mean)             CT+GLED (iv) VS CT   20 ml/day      12 days
  Zhou, B., 2012       III-IV                43/43              56--72 (range)        58--76 (range)                  CT+GLED (iv) VS CT   25 ml/day      28 days
  Zhou, C. Y., 2015    NG                    25/30              NG                    NG                              CT+GLED (iv) VS CT   20-30 ml/day   10 days
  Zou, D.H., 2009      II-IV                 100/100            40--92                38--94                          CT+GLED (iv) VS CT   20 ml/day      days

**Notes:** Con, control group (conventional treatments alone group); Exp, experimental group (conventional treatments and GLED combined group).

\*The compositions and concentrations of GLED in all included trials are the same (every 10 ml GDI contained 9.0--11.0 mg total flavonoids and 3.6--4.4 mg dipyridamole).

**Abbreviations:** CT, conventional treatments; NG, not given; NYHA, New York Heart Association; GLED, Ginkgo leaf extract and dipyridamole injection; IV, intravenous injection.

Quality assessment {#sec3-3}
------------------

The assessment of bias risk is shown in [Figure 2](#F2){ref-type="fig"}. Twenty-seven studies were determined as low risk, while one trial \[[@B26]\] did not provide a clear description of the randomization process. All included trials did not provide clear description of performance and detection risks. The attrition risks of involved trials were low. Three trials \[[@B25],[@B43],[@B48]\] were considered as high reporting risk owing to lack of primary outcomes (MER or TER) and 15 studies \[[@B25],[@B26],[@B28],[@B32],[@B35],[@B37],[@B42]\] were considered as unclear reporting risk due to lack of safety assessment.

![Risk of bias summary\
Review of authors' judgments about each risk of bias item for included studies. **Note:** Each color represents a different level of bias: red for high-risk, green for low-risk, and yellow for unclear-risk of bias.](bsr-40-bsr20200099-g2){#F2}

TER and MER {#sec3-4}
-----------

Twenty-five clinical trials \[[@B24],[@B26],[@B44],[@B49]\] involving 2,153 cases compared the MER and/or TER between the two groups ([Figures 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Our pooled results showed that CCP patients underwent combined therapy had significantly increased MER (RR = 1.44, 95% CI = 1.31--1.58, *P* \< 0.00001) and TER (RR = 1.28, 95% CI = 1.18--1.38, *P* \< 0.00001) compared with conventional treatments alone. MER (*P* = 0.92, *I*^2^ = 0%) was not heterogeneous among the studies, so fixed-effect model was used to analyzing its RR. Otherwise, random-effect model was used.

![Comparisons of MER between experimental and control group\
Forest plot of the comparison of MER between the experimental and control group. Control group, conventional treatments alone group; Experimental group, conventional treatments and GLED combined group. The random effects meta-analysis model (Inverse Variance method) was used.](bsr-40-bsr20200099-g3){#F3}

![Comparisons of TER between experimental and control group\
Forest plot of the comparison of TER between the experimental and control group. Control group, conventional treatments alone group; Experimental group, conventional treatments and GLED combined group. The random effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-40-bsr20200099-g4){#F4}

Blood gas analysis {#sec3-5}
------------------

Eight trials \[[@B27],[@B29],[@B30],[@B33],[@B35],[@B38],[@B39],[@B49]\] with 722 participants measured the PaO~2~ and PaCO~2~, two trials \[[@B27],[@B29]\] involving 142 CCP patients evaluated the SaO~2~, and three trials \[[@B27],[@B35],[@B39]\] including 316 patients reported data on pH value ([Figure 5](#F5){ref-type="fig"}). Results showed that the blood gas indexes of CCP patients received combined therapy was obviously improved compared with those treated by conventional treatments alone, indicated by significantly increased PaO~2~ (MD = 1.14, 95% CI = 0.89--1.39, *P* \< 0.00001)~,~ SaO~2~ (MD = 5.34, 95% CI = 3.65--7.04, *P* \< 0.00001) and PH value (MD = 0.11, 95% CI = 0.00--0.22, *P* = 0.05), and obviously decreased PaCO~2~ (MD = -0.52, 95% CI = -0.73--0.32, *P* \< 0.00001). PH value (*P* = 0.99, *I*^2^ = 0%) was heterogeneous among the studies, so random-effect model was used to analyzing its RR. Otherwise, fixed-effect model was used.

![Comparisons of blood gas indexes between experimental and control group\
Forest plot of the comparison of the blood gas indexes including PaO~2~ (**A**), PaCO~2~ (**B**), SaO~2~ (**C**) and PH value (**D**) between the experimental and control group. Control group, conventional treatments alone group; Experimental group, conventional treatments and GLED combined group.](bsr-40-bsr20200099-g5){#F5}

Hemorrheology assessment {#sec3-6}
------------------------

The hemorrheology of CCP patients was measured between GLED and non-GLED groups in 13 controlled studies \[[@B25],[@B29],[@B31],[@B34],[@B36],[@B37],[@B39],[@B41],[@B43],[@B44],[@B48]\] with 1,192 CCP patients ([Figure 6](#F6){ref-type="fig"}). In this analysis, our results showed that the hemorrheology of CCP patients received combined therapy was significantly ameliorated compared with those treated by conventional treatments alone, indicated by significantly decreased PV (MD = -0.21, 95% CI = -0.32--0.11, *P* \< 0.0001), WBHSV (MD = -1.07, 95% CI = -1.41--0.74, *P* \< 0.00001), WBMSV (MD = -1.91, 95% CI = -3.22--0.59, *P* = 0.004), WBLSV (MD = -2.17, 95% CI = -3.25--1.10, *P* \< 0.0001), hematocrit (MD = -0.06, 95% CI = -0.09--0.04, *P* \< 0.0001) and FBG (MD = -0.69, 95% CI = -1.01--0.37, *P* \< 0.0001), whereas analysis of EAI (MD = -0.36, 95% CI = -0.75-0.03, *P* = 0.07) did not differ significantly between the two groups. There was significant heterogeneity among the studies. Therefore, a random-effects model was conducted to pool data and so any conclusions need to be made with caution.

![Comparisons of hemorrheology indexes between experimental and control group\
Forest plot of the comparison of the hemorrheology indexes including PV (**A**), WBHSV (**B**), WBMSV (**C**), WBLSV (**D**), hematocrit (**E**), EAI (**F**) and FBG (**G**) between the experimental and control group. Control group, conventional treatments alone group; Experimental group, conventional treatments and GLED combined group. The random effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-40-bsr20200099-g6){#F6}

Adverse events assessment {#sec3-7}
-------------------------

Among all included studies, 18 trials \[[@B25],[@B26],[@B28],[@B32],[@B35],[@B37],[@B42]\] did not report adverse events. Ten trials \[[@B24],[@B27],[@B29],[@B33],[@B34],[@B36],[@B40],[@B41]\] involving 795 CCP patients described specific adverse events that occurred in GLED treatment. The most common side effects of GLED treatment were including nausea, headache, dizziness, abdominal distention, pruritus and skin rash, which usually subsided after symptomatic treatment. No severe adverse event occurred during GLED treatment, and the occurrence of these adverse reactions in the two groups did not differ obviously ([Figure 7](#F7){ref-type="fig"}, RR = 2.21, 95% CI = 0.95--5.15, *P* = 0.07). Statistics showed no statistically significant heterogeneity (*P* = 0.42, *I*^2^ = 0%), so fixed-effect model was used to carry out the meta-analysis.

![Comparisons of total adverse effects between experimental and control group\
Forest plot of the comparison of total adverse effects between the experimental and control group. Control group, conventional treatments alone group; Experimental group, conventional treatments and GLED combined group. The fixed-effects meta-analysis model (Mantel--Haenszel method) was used.](bsr-40-bsr20200099-g7){#F7}

Publication bias {#sec3-8}
----------------

Publication bias was assessed by funnel plots, Begg's and Egger's regression tests ([Figure 8](#F8){ref-type="fig"}). Analysis results indicate that publication bias was existed in MER and TER. To determine if the bias affect the results of pooled analysis, we conducted trim and filled analysis. The adjusted RR indicated same trend with the result of the primary analysis ([Figure 8](#F8){ref-type="fig"}, MER: before: *P* \< 0.001, after: *P* \< 0.001; TER: before: *P* \< 0.001, after: *P* \< 0.001), reflecting the reliability of our primary conclusions.

![Funnel plot of MER (A) and TER (B)](bsr-40-bsr20200099-g8){#F8}

Sensitivity analysis {#sec3-9}
--------------------

Sensitivity analysis was performed to explore an individual study's influence on the pooled results by deleting one single study each time from pooled analysis. As [Figure 9](#F9){ref-type="fig"} signified, the results revealed that no individual studies significantly affected the primary indicators (MER and TER), which indicated statistically robust results.

![Sensitivity analysis for MER (A) and TER (B)](bsr-40-bsr20200099-g9){#F9}

We also conducted subgroup analysis to explore the source of heterogeneity in MER and TER with respect to GLED dosages, duration of treatment, sample sizes of involved studies, and manufacturer of GLED. As shown in [Table 2](#T2){ref-type="table"}, our analysis showed that these variables except manufacturer of GLED did not have a significant impact on the therapeutic efficacy of GLED for CCP.

###### Subgroup analyses of MER and TER between the experimental and control group

  Parameter   Factors at study level         Experimental group, No. of patients (*n*)   Control group, No. of patients (*n*)   Analysis method   Heterogeneity   Risk ratio (RR)   95% CI   *P*-value    
  ----------- ------------------------------ ------------------------------------------- -------------------------------------- ----------------- --------------- ----------------- -------- ------------ -----------
  MER         **Dosage of GLED (DG)**                                                                                                                                                                     
              20\< DG ≤ 40 ml/day            189                                         188                                    Fixed             16              0.31              1.32     1.08--1.61   0.006
              15≤ DG ≤ 20 ml/day             774                                         760                                    Fixed             0               0.98              1.49     1.34--1.66   \<0.00001
              **Duration of treatment**                                                                                                                                                                   
              ≥14 days                       364                                         362                                    Fixed             0               0.70              1.38     1.19--1.60   \<0.0001
              \<14 days                      520                                         501                                    Fixed             0               0.69              1.48     1.31--1.68   \<0.00001
              **Manufacturer of the GLED**                                                                                                                                                                
              I                              70                                          70                                     Fixed             0               0.82              1.77     0.99--3.16   0.05
              II                             92                                          91                                     Fixed             0               0.42              1.34     1.02--1.76   0.03
              III                            322                                         323                                    Fixed             0               0.87              1.47     1.26--1.70   \<0.00001
              IV                             30                                          25                                     Fixed                                               1.13     0.73--1.76   0.58
              **Study sample size**                                                                                                                                                                       
              \>80                           596                                         582                                    Fixed             0               0.53              1.42     1.27--1.58   \<0.00001
              ≤80                            397                                         391                                    Fixed             0               0.97              1.48     1.25--1.75   \<0.00001
  TER         **Dosage of GLED**                                                                                                                                                                          
              20\< DG ≤ 40 ml/day            283                                         265                                    Fixed             49              0.08              1.27     1.16--1.39   \<0.00001
              15≤ DG ≤ 20 ml/day             777                                         773                                    Random            76              \<0.00001         1.30     1.18--1.44   \<0.00001
              **Duration of treatment**                                                                                                                                                                   
              ≥14 days                       486                                         467                                    Random            69              0.0004            1.27     1.14--1.41   \<0.0001
              \<14 days                      495                                         486                                    Random            74              \<0.0001          1.29     1.14--1.48   0.0001
              **Manufacturer of the GLED**                                                                                                                                                                
              I                              70                                          70                                     Fixed             0               0.70              1.43     1.18--1.74   0.0003
              II                             92                                          91                                     Fixed             0               0.59              1.19     1.04--1.36   0.01
              III                            322                                         323                                    Fixed             31              0.18              1.26     1.16--1.36   \<0.00001
              IV                             30                                          25                                     Fixed                                               1.11     0.91--1.35   0.29
              **Study sample size**                                                                                                                                                                       
              \>80                           519                                         496                                    Random            67              0.0001            1.30     1.16--1.45   \<0.00001
              ≤80                            571                                         567                                    Random            75              \<0.0001          1.26     1.13--1.40   \<0.0001

**Notes:** Con, control group (conventional treatments alone group); Exp, experimental group (conventional treatments and GLED combined group); I, Shanxi Pude Pharmaceutical Co., Ltd.; II, Hubei Minkang Pharmaceutical Co., Ltd.; III, Guizhou Yibai Pharmaceutical Co., Ltd.; IV, Tonghua Guhong Pharmaceutical Co., Ltd.

**Abbreviations:** GLED: Ginkgo leaf extract and dipyridamole injection; MER: Markedly effective rate; TER: Total effective rate.

Discussion {#sec4}
==========

Ginkgo biloba, a "living fossil," have been used as traditional herbal medicine for thousands of years in China \[[@B16]\]. As an important Ginkgo biloba extract preparation, it has been proven that the pharmacological effects of GLED include regulating vasomotor, improving hemorheology, enhancing immunity, relieving inflammation and scavenging free radicals \[[@B14],[@B15],[@B57]\]. It has been clinically applied as an effective complementary drug for lung and heart disease \[[@B14],[@B15],[@B58]\]. Even though there was statistical analysis of published literatures, a comprehensive and systematic evaluation of GLED for the treatment of CCP is still rare. In this analysis, we conducted a wide range of online search according strict eligibility criteria, by which to provide an internationally accessible systematic review of the clinical efficacy and safety of GLED for the CCP.

The meta-analysis was carried out in 25 articles \[[@B24],[@B26],[@B44],[@B49]\] to evaluate the therapeutic effects of GLED for CCP. Compared with conventional treatments alone, GLED combined with conventional treatments was associated with obviously higher MER and TER. Moreover, because of chronic hypoxia, patients with CCP will suffer from oxygen free radicals metabolism imbalance, increased blood viscosity and pulmonary artery pressure, and further lead to the right heart dysfunction and even failure \[[@B1]\]. Our analysis results showed that the blood gas and hemorheology indexes of patients were also significantly ameliorated after conventional treatments and GLED combined therapy. All these results indicated that GLED can improve the cardiopulmonary function of CCP patients effectively, which may be related with its action on regulating the blood viscosity and blood gas indexes. To further confirm whether some variable factors affect the therapeutic effects of GLED for CCP. We used four clinical variables (GLED dosages, duration of treatment, sample sizes of involved studies, and manufacturer of GLED) to interact with two outcome indicators (MER and TER) and found that the MER and TER might be associated with manufacturer of GLED. However, given that only one study \[[@B50]\] reported the use of GLED produced by Tonghua Guhong Pharmaceutical Co., Ltd., therefore it is not enough to draw a definitive conclusion at present.

Safety is the top priority of a therapeutic strategy, and special attention should be paid to adverse drug events. The most common side effects during GLED therapy were nausea, headache, dizziness, abdominal distention, pruritus and skin rash, and the total adverse events did not differ significantly between the two groups. Therefore, GLED is a relatively safe auxiliary medicine for CCP. However, evidence was limited to make a conclusion on safety evaluation because only 10 studies mentioned the adverse events.

There are some limitations in our analysis. First, as an important Chinese herb preparation, GLED was mainly applied in China or other Asian countries, which may bring the unavoidable regional bias and subsequently influence the clinical application of GLED worldwide. Second, the duration of treatment ranged from 7 to 28 days among the included studies. All of the trials assessed the efficacy immediately after the termination of the treatment period. Therefore, the long-term effect of GLED for CCP still needs methodologically rigorous trials to verify. Third, the main pathological features of CCP are pulmonary artery pressure, progressive of right ventricular hypertrophy and cardiopulmonary functional insufficiency. Many key variables, such as number of exacerbation, heart and lung function, quality of life, which closely related to survival, are not evaluated in these studies. Therefore, it is not yet possible to draw a conclusion on important outcomes. Moreover, GLED is a mixture that consists of more than one effective component, in this case, the mechanism of GLED may be complex and has multiple targets, and also this limits the usage of it. Fourthly, the administration conditions (extract/distill methods, storage conditions, dripping speed, GLED dosages and manufacturer, et al.) might be related with the efficacy of GLED mediated therapy \[[@B61],[@B62]\]. In order to achieve the clinical therapeutic effect and reduce the incidence of adverse reactions of GLED mediated therapy to the greatest extent, it is necessary to strengthen the supervision of clinical medication to standardize the rational medication. The GLED in all included trials was approved by Chinese State Food and Drug Administration (SFDA), and granted the Manufacturing Approve Number issued by Chinese SFDA (Supplementary Table S2). Based on currently available literatures, we have conducted subgroup analysis according to different GLED dosages and manufacturer. However, there are insufficient data to perform a statistical analysis to evaluate the impacts of other variable factors (extract/distill methods, storage conditions and dripping speed, et al.) on the treatment effect of GLED. We will keep following up with upcoming clinical trials to obtain relevant data when available. Finally, allocation concealment and blind method were not clear in most included studies, which may results in exaggerated estimates of treatment effect. Given the limitations mentioned above, all the findings from our study should be dealt with some caution.

Conclusion and prospect {#sec5}
=======================

In summary, our meta-analysis suggested that GLED could have potential therapeutic effects and be relatively safe for the treatment of CCP. Clinical application of GLED not only obviously enhanced the therapeutic effects of conventional treatments, but also useful in lowering plasma viscosity, blood viscosity, hematocrit, alleviating and improving PaO~2~ and SaO~2~ of CCP patients. However, due to the publication bias and low quality of some included trials increases risks and bias, the clinical efficacy and safety of GLED-mediate therapy for CCP still needs more high-quality, multi-center large randomized trials to verify.

Traditional Chinese medicine plays an increasingly important role in various disease treatments (such as malaria and 2019 novel coronavirus, etc.) \[[@B16],[@B63]\]. Ginkgo leaf extract has been used for pharmaceutical and medicinal purpose in China for several hundred years to treat various diseases \[[@B16]\]. The extremely low rate of side effects and good tolerance together with its pharmacological mechanism will make GLED a promising therapeutic drug in cardiovascular disease, peripheral vascular disease and pulmonary disease worldwide \[[@B16]\].
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CCP

:   chronic cor pulmonale

CI

:   confidence interval

EAI

:   erythrocyte aggregation index

FBG

:   content of fibrinogen

GLED

:   Ginkgo leaf extract and dipyridamole injection

MD

:   mean difference

MER

:   markedly effective rate

NYHA

:   New York Heart Association

PaCO~2~

:   partial pressure of carbon dioxide

PaO~2~

:   partial pressure of oxygen

PRISMA

:   Preferred Reporting Items for Systematic Reviews

PV

:   plasma viscosity

RCT

:   randomized controlled trial

RR

:   risk ratio

SaO~2~

:   saturation of hemoglobin with oxygen

TER

:   total effective rate

WBHSV

:   whole blood high-shear viscosity

WBLSV

:   whole blood low-shear viscosity

WBMSV

:   whole blood medium-shear viscosity

WHO

:   World Health Organization
